Kymera Therapeutics Inc (KYMR) Stock Price, Quote & News

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 5300

Website: www.kymeratx.com

Address:

500 North Beacon Street, 4th Floor, Watertown, United States

TopTierNewswire Jun. 23 at 4:11 AM

$BJRI $KYMR $FLEX all have massive recent insider sales.

0 · Reply

Volatility_Viking Jun. 23 at 3:45 AM

$KYMR

0 · Reply

MikeyNJ Jun. 22 at 2:15 PM

$KYMR If AbbVie is paying $11B for Apogee, KYMR is worth a lot more.

0 · Reply

Trainguy1 Jun. 22 at 1:56 PM

$KYMR Yay, we got to $100/sh!

0 · Reply

Doozio Jun. 17 at 9:07 PM

$KYMR a biotech bonanza is coming ONTO 🐒🍌🧠⏰♾️

0 · Reply

Merlintrader Jun. 12 at 5:02 PM

$MBX Biotech Tape in Focus: $MBX Strengthens Phase 3 Setup, $JAZZ Hits Oncology Trial Risk, $KYMR Adds Platform Momentum https://www.merlintrader.com/biotech-tape-mbx-jazz-kymr/

0 · Reply

MaverikIT Jun. 12 at 2:41 PM

@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character Yo, $TGTX +1.55 knocking on 50'$ $PRAX $KYMR and awesome$ $AXSM

2 · Reply

PolycarpFX Jun. 6 at 5:40 PM

$KYMR New Write up for Kymera Therapeutics, link in comments and website can be found on my profile.

1 · Reply

Arcides Jun. 2 at 5:40 PM

will bios lead the falling? pupu $KYMR $XBI

0 · Reply

SuperGreenToday May. 27 at 5:05 PM

$KYMR Share Price: $81.50 Contract Selected: Nov 20, 2026 $105 Calls Buy Zone: $4.42 – $5.46 Target Zone: $8.27 – $10.11 Potential Upside: 77% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Kymera Therapeutics participates in a conference call with JPMorgan

Jun 12, 2026, 7:00 AM EDT - 11 days ago

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Jun 11, 2026, 7:14 AM EDT - 12 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Jun 9, 2026, 7:00 AM EDT - 14 days ago

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Jun 9, 2026, 7:00 AM EDT - 14 days ago

Kymera Therapeutics Slides: Corporate presentation

Jun 8, 2026, 4:01 PM EDT - 15 days ago

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

2026-06-08T13:14:14.000Z - 15 days ago

Kymera Therapeutics presents preclinical lupus data for KT-579

Jun 8, 2026, 7:00 AM EDT - 15 days ago

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Jun 3, 2026, 8:10 AM EDT - 20 days ago

Kymera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 7:00 AM EDT - 27 days ago

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 19, 2026, 9:00 AM EDT - 5 weeks ago

Kymera Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

May 12, 2026, 12:20 PM EDT - 6 weeks ago

Kymera Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T10:32:55.000Z - 6 weeks ago

Kymera Therapeutics initiated with a Buy at Canaccord

2026-05-07T09:31:29.000Z - 6 weeks ago

Kymera Therapeutics initiated with a Buy at Canaccord

May 6, 2026, 7:00 AM EDT - 6 weeks ago

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

2026-04-30T18:14:22.000Z - 7 weeks ago

Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley

Apr 30, 2026, 8:30 AM EDT - 7 weeks ago

Kymera Therapeutics Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 7 weeks ago

Kymera Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 7 weeks ago

Kymera Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 7 weeks ago

Kymera Therapeutics Slides: Q1 2026

2026-04-30T11:54:48.000Z - 7 weeks ago

Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)

Apr 30, 2026, 7:00 AM EDT - 7 weeks ago

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Kymera Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Kymera Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

2026-04-13T11:13:32.000Z - 2 months ago

FDA grants fast track designation to Kymera Therapeutics KT-621

Apr 13, 2026, 7:00 AM EDT - 2 months ago

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

2026-03-29T14:31:15.000Z - 3 months ago

Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621

Mar 28, 2026, 11:00 AM EDT - 3 months ago

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

2026-03-16T13:39:52.000Z - 3 months ago

Kymera Therapeutics assumed with a Buy at Jefferies

Mar 12, 2026, 9:30 AM EDT - 3 months ago

Kymera Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 11:20 AM EDT - 3 months ago

Kymera Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

Mar 3, 2026, 9:10 AM EST - 4 months ago

Kymera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-03T13:50:17.000Z - 4 months ago

Kymera Therapeutics price target raised to $128 from $90 at UBS

2026-03-02T12:23:23.000Z - 4 months ago

Kymera Therapeutics price target raised to $100 from $95 at Stephens

2026-03-02T11:52:32.000Z - 4 months ago

Kymera Therapeutics price target raised to $120 from $110 at Citi

2026-02-26T20:36:54.000Z - 4 months ago

Kymera Therapeutics price target lowered to $123 from $127 at Morgan Stanley

Feb 26, 2026, 2:00 PM EST - 4 months ago

Kymera Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-26T14:00:20.000Z - 4 months ago

Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler

Feb 26, 2026, 8:30 AM EST - 4 months ago

Kymera Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Kymera Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Kymera Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Kymera Therapeutics Slides: Q4 2025

2026-02-26T12:14:14.000Z - 4 months ago

Kymera Therapeutics reports Q4 EPS (97c), consensus (79c)

Feb 26, 2026, 7:00 AM EST - 4 months ago

Kymera Therapeutics Slides: Corporate presentation

Feb 19, 2026, 7:00 AM EST - 4 months ago

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 11, 2026, 9:00 AM EST - 4 months ago

Kymera Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-01-29T12:21:08.000Z - 5 months ago

Kymera Therapeutics initiates dosing in BREADTH Phase 2b trial of KT-621

2026-01-27T21:31:37.000Z - 5 months ago

Kymera Therapeutics assumed with an Overweight at Barclays

Jan 13, 2026, 12:00 PM EST - 5 months ago

Kymera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:00 PM EST - 5 months ago

Kymera Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:00 AM EST - 5 months ago

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Dec 11, 2025, 4:01 PM EST - 6 months ago

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 8, 2025, 4:01 PM EST - 7 months ago

Kymera Therapeutics Announces Proposed Public Offering

Dec 8, 2025, 3:50 PM EST - 7 months ago

This Drugmaker's Stock Is Soaring Over 40% Monday

Dec 8, 2025, 8:00 AM EST - 7 months ago

Kymera Therapeutics Transcript: Study Result

Dec 8, 2025, 8:00 AM EST - 7 months ago

Kymera Therapeutics Press release: Study Result

Dec 8, 2025, 8:00 AM EST - 7 months ago

Kymera Therapeutics Slides: Study Result

Dec 8, 2025, 7:42 AM EST - 7 months ago

Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.

Dec 8, 2025, 7:00 AM EST - 7 months ago

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Dec 5, 2025, 4:01 PM EST - 7 months ago

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Dec 4, 2025, 8:45 AM EST - 7 months ago

Kymera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 11:15 AM EST - 7 months ago

Kymera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 2:30 PM EST - 7 months ago

Kymera Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 7 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Nov 24, 2025, 7:00 AM EST - 7 months ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Nov 19, 2025, 6:00 AM EST - 7 months ago

Kymera Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 10:30 AM EST - 7 months ago

Kymera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 1:20 PM EST - 8 months ago

Kymera Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 11:45 AM EST - 8 months ago

Kymera Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 9:00 AM EST - 8 months ago

Kymera Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 9, 2025, 6:00 PM EST - 8 months ago

Kymera Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 8:30 AM EST - 8 months ago

Kymera Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Kymera Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Kymera Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Kymera Therapeutics Slides: Q3 2025

Nov 3, 2025, 7:00 AM EST - 8 months ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Nov 3, 2025, 7:00 AM EST - 8 months ago

Kymera Therapeutics Slides: Corporate Presentation

Oct 28, 2025, 7:00 AM EDT - 8 months ago

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Sep 15, 2025, 12:30 PM EDT - 10 months ago

Kymera Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 9, 2025, 12:20 PM EDT - 10 months ago

Kymera Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 9:30 AM EDT - 10 months ago

Kymera Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 10:30 AM EDT - 10 months ago

Kymera Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Aug 27, 2025, 7:00 AM EDT - 10 months ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Aug 12, 2025, 9:47 AM EDT - 11 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY

Aug 11, 2025, 8:30 AM EDT - 11 months ago

Kymera Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 11 months ago

Kymera Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 11 months ago

Kymera Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 11 months ago

Kymera Therapeutics Slides: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Jun 26, 2025, 11:56 PM EDT - 1 year ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Jun 25, 2025, 9:15 AM EDT - 1 year ago

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

GILD

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Kymera Therapeutics Transcript: AGM 2025

Jun 25, 2025, 7:05 AM EDT - 1 year ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

GILD

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Kymera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 4:16 PM EDT - 1 year ago

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial

Jun 5, 2025, 8:45 AM EDT - 1 year ago

Kymera Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Transcript: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Press release: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Slides: Study Result

Jun 2, 2025, 7:44 AM EDT - 1 year ago

Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

May 30, 2025, 4:01 PM EDT - 1 year ago

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

May 29, 2025, 7:00 AM EDT - 1 year ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

May 19, 2025, 12:15 PM EDT - 1 year ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

May 14, 2025, 6:40 PM EDT - 1 year ago

Kymera Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Quarterly report: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Earnings release: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Slides: Q1 2025

May 9, 2025, 7:01 AM EDT - 1 year ago

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

May 9, 2025, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

May 7, 2025, 7:00 AM EDT - 1 year ago

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kymera Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 9:10 AM EST - 1 year ago

Kymera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 8:30 AM EST - 1 year ago

Kymera Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Kymera Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Kymera Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Kymera Therapeutics Slides: Q4 2024

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Feb 11, 2025, 11:20 AM EST - 1 year ago

Kymera Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 10:00 AM EST - 1 year ago

Kymera Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Jan 14, 2025, 12:00 PM EST - 1 year ago

Kymera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 12:00 PM EST - 1 year ago

Kymera Therapeutics Slides: FY 2025

Jan 14, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

TopTierNewswire Jun. 23 at 4:11 AM

$BJRI $KYMR $FLEX all have massive recent insider sales.

0 · Reply

Volatility_Viking Jun. 23 at 3:45 AM

$KYMR

0 · Reply

MikeyNJ Jun. 22 at 2:15 PM

$KYMR If AbbVie is paying $11B for Apogee, KYMR is worth a lot more.

0 · Reply

Trainguy1 Jun. 22 at 1:56 PM

$KYMR Yay, we got to $100/sh!

0 · Reply

Doozio Jun. 17 at 9:07 PM

$KYMR a biotech bonanza is coming ONTO 🐒🍌🧠⏰♾️

0 · Reply

Merlintrader Jun. 12 at 5:02 PM

$MBX Biotech Tape in Focus: $MBX Strengthens Phase 3 Setup, $JAZZ Hits Oncology Trial Risk, $KYMR Adds Platform Momentum https://www.merlintrader.com/biotech-tape-mbx-jazz-kymr/

0 · Reply

MaverikIT Jun. 12 at 2:41 PM

@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character Yo, $TGTX +1.55 knocking on 50'$ $PRAX $KYMR and awesome$ $AXSM

2 · Reply

PolycarpFX Jun. 6 at 5:40 PM

$KYMR New Write up for Kymera Therapeutics, link in comments and website can be found on my profile.

1 · Reply

Arcides Jun. 2 at 5:40 PM

will bios lead the falling? pupu $KYMR $XBI

0 · Reply

SuperGreenToday May. 27 at 5:05 PM

0 · Reply

MarketBeat May. 26 at 1:08 PM

https://marketbeat.com/a/8675728/ $KYMR Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data

0 · Reply

NVDAMillionaire May. 13 at 9:48 PM

$KYMR Really good write-up that perfectly summarizes KYMR's present situation. So if you want to bring your KYMR knowledge up to date or just discover KYMR, this is required reading. https://everyticker.com/quote/KYMR/analysis/kymera-therapeutics-the-48-billion-oral-biologics-opportunity-meets-a-2029-cash-runway-nasdaq-kymr

0 · Reply

vjtweet May. 7 at 2:58 AM

$KYMR why not hatch some money in this?

0 · Reply

MikeyNJ May. 6 at 11:50 AM

$KYMR Canaccord initiates coverage with a $106 target.

0 · Reply

justiceforb_85 May. 5 at 5:42 PM

$KYMR KT-579 will be a game changer. This remains undervalued.

0 · Reply

d_risk Apr. 30 at 3:38 PM

$KYMR - Kymera Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +252.7% above peer average (42,090 vs 11,934 across 652 peers). KYMR’s 10-Q adds fresh emphasis on early-stage clinical status, ongoing losses and dilution risk, clinical trial and safety uncertainty, IP and cyber/data vulnerabilities, macro/geopolitical shocks, stock volatility and control issues, plus governance, tax, internal controls and anti-takeover provisions that may constrain investor influence and upside. 🟢 Added 🟠 Removed https://d-risk.ai/KYMR/10-Q/2026-04-30

0 · Reply

StocktwitsEarnings Apr. 30 at 11:15 AM

$KYMR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.71 up 13.41% YoY • Reported revenue of $34.37M up 55.50% YoY • Kymera Therapeutics expects its $1.55 billion cash balance as of March 31, 2026, will provide a cash runway into 2029, supporting multiple clinical inflection points in its pipeline.

0 · Reply

BillionerOfKing Apr. 28 at 3:32 AM

$KYMR Current Stock Price: $86.77 Contracts to trade: $85.0 KYMR May 15 2026 Call Entry: $5.60 Exit: $9.61 ROI: 72% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

frenulum1 Apr. 23 at 12:51 PM

$KYMR $86 was the Baker Bros biggest buy in price..

0 · Reply

Keystone1 Apr. 13 at 1:13 PM

$KYMR https://finance.yahoo.com/sectors/healthcare/articles/kymera-therapeutics-announces-u-fda-110000460.html

0 · Reply

Keystone1 Apr. 9 at 12:29 PM

$KYMR https://finance.yahoo.com/sectors/healthcare/articles/kymera-therapeutics-announces-gilead-sciences-110000333.html

0 · Reply

Doozio Apr. 8 at 5:12 AM

$KYMR 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	7.44B
Revenue (ttm)	39.21M
Net Income (ttm)	-311.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-794.06%
Debt to Equity Ratio	0.00

Volume	1,368,156
Avg Vol	604,566
Day's Range	N/A - N/A
Shares Out	82.26M
Stochastic %K	83%
Beta	2.02
Analysts	Strong Sell
Price Target	$118.55